New monoclonal antibody selectively targets PCa sites
New York-A newer monoclonal antibody is showing a canny ability to target prostate cancer cells in both bony and soft tissue, and its therapeutic potential is now undergoing testing. Neil Bander, MD, and colleagues from New York Presbyterian-Weill Cornell Medical Center developed the antibody, dubbed J591 (licensed by BZL Biologics, Inc., Framingham, MA, and sub-licensed by Millennium Pharmaceuticals, Cambridge, MA).
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.